Fig. 2.
MOv18-IgE inhibits the growth of IGROV1 human ovarian adenocarcinoma cells in vivo in the presence of human PBMC as effectors. A matched variable region set of mouse/human chimeric IgE and IgG1 antibodies specific for FBP was tested for their ability to inhibit the s.c. growth of cells in a SCID mouse xenograft model of human ovarian cancer. Mice were treated i.p. with anti-asialo GM1 to eliminate host natural killer cells. One day later, mice were challenged s.c. with 2 × 106 IGROV1 cells followed by i.v. injection of 2.5 × 106 human PBMC combined with either 100 μg MOv18-IgG1, 100 μg MOv18-IgE or 50 μg MOv18-IgE. The mean tumor size ± the standard error of the mean measured on days 19, 29, and 35 is shown (n = 4 for all groups). Adapted and printed from Figure 4A Gould et al. [43] with permission. Copyright Wiley–VCH Verlag GmbH & Co. KGaA